Menu
Press releases

(French) BCG et cancer de la vessie : vers un nouveau protocole pour les patients ?

Sorry, this press release is only available in French.

Medias
Press Contact
Service de presse de l’Institut Pasteur Sabine D’Andrea - 01 44 38 92 17 Nadine Peyrolo - 01 45 68 81 46
Sources
Pre-existing BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer, Science Translational Medicine, 6 juin 2012 Claire Biot1,2,3, Cyrill A. Rentsch1,2,4*, Joel R. Gsponer1,2,4*, Frédéric D. Birkhäuser5, Hélène Jusforgues-Saklani1,2, Fabrice Lemaître6,7, Charlotte Auriau1,2, Alexander Bachmann5, Philippe Bousso6,7, Caroline Demangel8, Lucie Peduto9, George N. Thalmann5, Matthew L. Albert1,2,10 1 Unité d’Immunobiologie des Cellules Dendritiques, Department of Immunology, Institut Pasteur, F-75724 Paris, France. 2 INSERM U818, F-75654 Paris, France. 3 Mines ParisTech, F-75272 Paris, France. 4 Department of Urology, University Hospital of Basel, CH-4031 Basel, Switzerland. 5 Department of Urology, University of Bern, Inselspital, CH-3010 Bern, Switzerland. 6 Unité des Dynamique des Réponses Immunes, Department of Immunology, Institut Pasteur, F-75724 Paris, France. 7 INSERM U668, F-75654 Paris, France. 8 Unité d’Immunobiologie de l’Infection, Department of Immunology, Institut Pasteur, F-75724 Paris, France. 9 Unité de Développement des Tissus Lymphoïdes, Department of Immunology, Institut Pasteur, F-75724 Paris, France. 10 Université Paris Descartes, F-75270 Paris, France. * These authors contributed equally to this work.
fermer